Human Adenovirus B Serotype 7 Strain 55142 Antigen

The administration of Human Adenovirus B Serotype 7 Strain 55142 Antigen follows a standardized, single-dose protocol. It is not a multi-dose series; a single successful administration is intended to provide long-term immunity for the duration of the high-risk period (e.g., basic training).

• Standard Adult Dose (Ages 17-50): One single oral tablet of Human Adenovirus Type 7 (Strain 55142) taken simultaneously with one single oral tablet of Human Adenovirus Type 4.
• Dosing Frequency: A single administration event. Boosters are not currently indicated or recommended under standard military protocols.

Human Adenovirus B Serotype 7 Strain 55142 Antigen is NOT approved for use in pediatric populations. The safety and efficacy of this live virus vaccine have not been established in individuals under the age of 17. Because the vaccine involves the shedding of a live, wild-type virus, the risks of transmission to more vulnerable pediatric populations are a significant concern.

Renal Impairment

There are no specific dosage adjustments provided for patients with renal impairment. Because the vaccine acts locally in the gut and is not cleared by the kidneys, renal function is not expected to impact the safety or efficacy of the vaccine. However, the overall health of the recruit is assessed prior to administration.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. The live virus replication occurs in the intestinal epithelium and does not involve hepatic metabolic pathways.

Elderly Patients

This vaccine is NOT approved for use in adults over the age of 50. Clinical trials did not include sufficient numbers of subjects in this age group to determine whether they respond differently than younger adults. Furthermore, the risk of adenovirus-related ARD is significantly lower in the general elderly population compared to military recruits.

Proper administration is critical to the safety of this vaccine. Because the tablet contains a live virus that can cause severe respiratory illness if inhaled or exposed to the upper airway, the following instructions must be strictly followed:

1. 1Swallow Whole: The tablet must be swallowed whole. NEVER crush, chew, or break the tablet. Breaking the enteric coating could release the live virus in the mouth or throat, potentially leading to a severe respiratory infection.
2. 2With or Without Food: The vaccine can be taken regardless of food intake, although it is typically administered in a group setting during medical processing.
3. 3Simultaneous Administration: The Type 7 tablet must be taken at the same time as the Type 4 tablet to ensure comprehensive protection against both prevalent strains.
4. 4Storage: The tablets must be stored under refrigeration between 2°C and 8°C (36°F to 46°F). They should not be frozen.

In the military setting, this vaccine is administered as a one-time dose during initial entry processing. If a dose is missed during the scheduled medical processing, it should be administered as soon as the omission is identified, provided the individual is still within the high-risk training environment.

There is no clinical data regarding the overdose of Human Adenovirus B Serotype 7 Strain 55142 Antigen. Since it is a live virus that replicates to a natural limit within the gut, a double dose would likely result in a similar immune response but might increase the intensity of gastrointestinal side effects. In the event of an accidental overdose (e.g., swallowing multiple tablets), the individual should be monitored for severe gastrointestinal distress and signs of respiratory infection. Emergency measures would be supportive.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to obtain this vaccine outside of authorized military medical channels.

Because Human Adenovirus B Serotype 7 Strain 55142 Antigen involves a live viral infection of the gastrointestinal tract, most common side effects are related to the body's immune response or the localized infection in the gut. These are typically mild and self-limiting.

• Headache: Reported by a significant percentage of vaccine recipients. It usually occurs within the first 72 hours and may feel like a dull tension headache.
• Upper Respiratory Tract Symptoms: Despite the enteric coating, some users report nasal congestion, sore throat, or a mild cough. This is often the body's systemic inflammatory response rather than a direct infection of the throat.
• Abdominal Pain: Mild cramping or discomfort in the mid-abdominal region as the virus replicates in the intestinal lining.
• Diarrhea: Loose stools may occur as the gut reacts to the viral presence.
• Nausea: A general feeling of stomach upset, usually occurring within the first week post-vaccination.

• Fever: A low-grade fever (99°F to 101°F) may occur as the immune system activates. This typically lasts 24-48 hours.
• Joint Pain (Arthralgia): General body aches or specific joint discomfort.
• Urinary Frequency: Some reports of increased urgency or frequency of urination have been noted in clinical trials.
• Loss of Appetite: A temporary decrease in desire to eat, often coinciding with gastrointestinal symptoms.

• Severe Allergic Reactions: Anaphylaxis is extremely rare but possible with any biological product.
• Severe Gastrointestinal Hemorrhage: Very rare reports of blood in the stool; any such symptom requires immediate evaluation.
• Pneumonia: While the vaccine is designed to prevent pneumonia, in rare cases of improper administration (chewing the tablet), a vaccine-induced respiratory infection could occur.

> Warning: Stop and call your doctor immediately or seek emergency care if you experience any of the following after receiving the vaccine:

• Difficulty Breathing or Swallowing: Signs of a severe allergic reaction (anaphylaxis) or accidental respiratory exposure to the live virus.
• High Fever: A fever exceeding 102°F (39°C) that does not respond to acetaminophen.
• Severe Abdominal Pain: Intense, localized pain that could indicate a more serious intestinal issue.
• Blood in Stool or Vomit: Indicates potential gastrointestinal bleeding.
• Neurological Changes: While not directly linked to this vaccine, any sudden confusion, weakness, or vision changes after a vaccination should be evaluated.

There are no known chronic or long-term side effects associated with the Human Adenovirus B Serotype 7 Strain 55142 Antigen. The virus is cleared from the system by the immune system within weeks. The primary "long-term" effect is the presence of protective antibodies, which is the intended therapeutic outcome.

There are no FDA black box warnings for Human Adenovirus B Serotype 7 Strain 55142 Antigen. However, there are significant "Warnings and Precautions" regarding the shedding of the live virus and the potential for transmission to susceptible contacts.

A critical aspect of this vaccine is that the recipient becomes a shedder of the live adenovirus type 7. For approximately 28 days after taking the tablet, the live virus is present in the recipient's feces. While this does not usually affect the recipient, it poses a risk to others. If the recipient does not practice strict hand hygiene, they could transmit the virus to household members or close contacts. If those contacts are immunocompromised or pregnant, the transmitted virus could cause severe illness. This is why the vaccine is currently restricted to military recruits who are generally isolated from these high-risk groups during their initial training period.

Report any unusual symptoms to your healthcare provider. In the military, this is usually done through the unit's medical officer or the Vaccine Adverse Event Reporting System (VAERS).

Human Adenovirus B Serotype 7 Strain 55142 Antigen is a live, potent biological agent. Its use is strictly regulated and requires adherence to specific safety protocols to prevent accidental infection of the recipient or their contacts. The most important safety rule is that the tablet must be swallowed whole. Any compromise to the tablet's integrity before it reaches the small intestine can result in a serious respiratory infection.

No FDA black box warnings for Human Adenovirus B Serotype 7 Strain 55142 Antigen.

• Viral Shedding and Transmission: The vaccine contains a live virus that is shed in the stool for up to 28 days. Recipients must be cautioned about the risk of transmitting the virus to close contacts, particularly those who are immunocompromised, pregnant, or have chronic medical conditions. Strict hand hygiene after using the restroom is mandatory.
• Allergic Reactions: Individuals with a known history of severe allergic reactions to any component of the vaccine (including microcrystalline cellulose, magnesium stearate, or the enteric coating materials) should not receive the vaccine.
• Immunosuppression: This vaccine should not be administered to individuals with suppressed immune systems, whether due to disease (e.g., HIV/AIDS, leukemia) or medical treatment (e.g., chemotherapy, high-dose steroids). In such individuals, the vaccine virus could replicate uncontrollably, leading to systemic illness.
• Concomitant Illness: Administration should be deferred in individuals suffering from acute severe febrile illness until they have recovered.

Routine lab tests are not typically required following the administration of this vaccine. However, medical officers in military settings monitor for:

• Outbreaks of ARD: To ensure the vaccine is providing effective herd immunity within the recruit population.
• Gastrointestinal Distress: Monitoring recruits who report severe abdominal pain or persistent diarrhea.
• Hand Hygiene Compliance: Ensuring that the facilities and protocols support the prevention of cross-contamination during the shedding period.

There is no evidence that Human Adenovirus B Serotype 7 Strain 55142 Antigen impairs the ability to drive or operate heavy machinery. However, if a recipient experiences significant headaches or malaise as a side effect, they should exercise caution until symptoms resolve.

There are no documented direct interactions between alcohol and the adenovirus vaccine. However, alcohol can irritate the gastrointestinal tract and may exacerbate the mild nausea or abdominal discomfort associated with the vaccine. Furthermore, alcohol can suppress the immune system, potentially interfering with the body's ability to mount an optimal response to the vaccine.

As this is a single-dose vaccine, "discontinuation" in the traditional sense does not apply. Once the tablet is swallowed, the viral replication process begins. There is no "reversal agent" for the vaccine, although the resulting infection is generally self-limiting and controlled by the host's immune system.

> Important: Discuss all your medical conditions with your healthcare provider before starting Human Adenovirus B Serotype 7 Strain 55142 Antigen. Ensure you disclose if you live with anyone who is pregnant, an infant, or has a weakened immune system.

• Immunosuppressive Therapies: Drugs such as high-dose corticosteroids (e.g., prednisone >20mg/day), TNF-alpha inhibitors (e.g., adalimumab, etanercept), and chemotherapy agents must NEVER be used concurrently with this live vaccine. The clinical consequence is a risk of disseminated viral infection, where the vaccine virus spreads beyond the gut and causes systemic disease because the body cannot check its replication.

• Other Live Vaccines: While the Type 4 and Type 7 adenovirus vaccines are designed to be taken together, the administration of other live vaccines (such as MMR or Varicella) should ideally be spaced by at least 4 weeks if not given on the same day. This is to prevent "interference," where the immune response to one vaccine diminishes the response to the other.
• Immune Globulin (IG): If a patient has recently received blood products or immune globulin, the antibodies present in those products might neutralize the vaccine virus before it can stimulate the recipient's own immune system. It is generally recommended to wait 3-11 months after IG administration before giving a live viral vaccine.

• Antiviral Medications: Drugs active against DNA viruses (such as cidofovir or acyclovir) could theoretically inhibit the replication of the vaccine virus, thereby reducing the vaccine's effectiveness. While adenovirus is not highly sensitive to acyclovir, more potent antivirals should be avoided during the 28-day shedding period.

• No major food interactions: The enteric coating protects the antigen from stomach acid, and clinical trials did not show significant changes in efficacy based on food intake. However, avoiding excessively spicy or irritating foods for 24 hours post-administration may help minimize gastrointestinal side effects.

• Echinacea and Immunostimulants: While often taken to "boost" the immune system, there is no clinical data on how these supplements interact with a live viral vaccine. They could theoretically alter the inflammatory response to the vaccine.
• High-dose Vitamin C: Unlikely to interfere with the vaccine, but should be disclosed to the healthcare provider.

• Stool Cultures: If a recipient's stool is cultured within 28 days of vaccination, it will likely test positive for Adenovirus Type 7. This is a result of the vaccine shedding and should not be mistaken for a community-acquired pathogenic infection unless symptoms warrant such a diagnosis.
• Tuberculin Skin Test (TST): Live viral vaccines can sometimes cause a temporary suppression of delayed-type hypersensitivity, leading to a false-negative TST (Mantoux test) result. It is recommended to perform the TST on the same day as vaccination or wait 4-6 weeks after vaccination.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. In the military, ensure your full medical record is updated during the pre-vaccination screening.

Human Adenovirus B Serotype 7 Strain 55142 Antigen must NEVER be used in the following circumstances:

1. 1Pregnancy: This is an absolute contraindication. Because the vaccine contains a live, wild-type virus that is shed systemically and in the stool, there is a theoretical risk of fetal infection or complications. Pregnant women are at higher risk for severe complications from adenovirus infection.
2. 2Severe Immunosuppression: Patients with primary or acquired immunodeficiency, including those with HIV/AIDS, cellular immunodeficiencies, or those receiving immunosuppressive therapy, must not receive this vaccine. The lack of an intact immune system allows the virus to replicate without restraint.
3. 3Severe Allergic Reaction: Anyone with a documented anaphylactic reaction to any previous dose of an adenovirus vaccine or any of its excipients.
4. 4Inability to Swallow Whole: If a patient has a medical condition (like severe dysphagia) that prevents them from swallowing the tablet whole, they cannot receive the vaccine due to the risk of respiratory exposure.

Conditions requiring careful risk-benefit analysis include:

• Nursing Mothers: It is unknown if the vaccine virus is secreted in human milk. However, the risk of transmission to the infant via fecal-oral contact with the mother is a significant concern.
• Close Contact with High-Risk Individuals: If a recruit is expected to have close contact with infants, elderly, or immunocompromised individuals within 28 days of vaccination, the administration should be carefully considered or delayed.
• Acute Gastrointestinal Illness: If a patient is currently experiencing vomiting or severe diarrhea, the vaccine may not be effective as the virus may be cleared before it can infect the intestinal lining.

There is no known cross-sensitivity with other common vaccines (like influenza or hepatitis). However, patients sensitive to the specific components of the enteric coating (such as cellulose acetate phthalate) should be identified.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Human Adenovirus B Serotype 7 Strain 55142 Antigen.

FDA Pregnancy Category: X (or equivalent in modern labeling). Human Adenovirus B Serotype 7 Strain 55142 Antigen is contraindicated in pregnant women. There are no adequate and well-controlled studies in pregnant women, but the potential for the live virus to cause harm to the fetus or the mother is considered to outweigh any potential benefit in this population. If a woman becomes pregnant within 6 weeks of receiving the vaccine, she should be counseled on the potential risks to the fetus. Military protocols require a negative pregnancy test for all females of childbearing potential prior to administration.

It is not known whether the vaccine virus or the resulting antibodies are excreted in human milk. The primary concern is not necessarily the milk itself, but the close physical contact between the mother and the infant. Because the mother will be shedding live virus in her stool for 28 days, the risk of transmitting the virus to the nursing infant is high. If a nursing mother must be vaccinated, extreme caution and rigorous hand hygiene are required, though generally, the vaccine is avoided in this population.

Safety and effectiveness in children under the age of 17 have not been established. The vaccine is not indicated for pediatric use. The risk of viral shedding to other children in a school or daycare setting makes this vaccine inappropriate for the general pediatric population.

Clinical studies of Human Adenovirus B Serotype 7 Strain 55142 Antigen did not include subjects aged 50 and over. It is not known if older adults respond differently. Given that the immune system's vigor often declines with age (immunosenescence), the safety of a live, non-attenuated virus in the elderly is not guaranteed. This vaccine is not approved for use in the geriatric population.

No specific studies have been conducted in patients with renal impairment. However, since the vaccine is not systemically absorbed and does not rely on renal clearance, no dosage adjustments are anticipated. The primary concern would be the patient's overall immune status if the renal impairment is part of a systemic disease.

No specific studies have been conducted in patients with hepatic impairment. Viral replication occurs in the gut, not the liver. Unless the hepatic impairment is associated with significant coagulopathy (increasing the risk of GI bleeding) or immunosuppression, it is not expected to interfere with the vaccine.

> Important: Special populations require individualized medical assessment. In the military, these cases are often referred to specialized infectious disease or immunology boards.

Human Adenovirus B Serotype 7 Strain 55142 Antigen works by inducing a protective immune response through a controlled, non-respiratory infection. The antigen is a live, wild-type (not weakened) adenovirus. When the enteric-coated tablet reaches the small intestine, it dissolves and releases the virus. The virus then infects the intestinal mucosal cells. This infection is usually asymptomatic because the adenovirus does not cause significant disease in the gut of healthy adults.

As the virus replicates, the gut-associated lymphoid tissue (GALT) recognizes the viral proteins. This stimulates the production of secretory IgA in the mucosa and systemic IgG antibodies. These antibodies are specific to the Serotype 7 hexon and fiber proteins. If the vaccinated individual later inhales wild-type Adenovirus Type 7, the pre-existing circulating antibodies neutralize the virus before it can cause febrile respiratory disease.

• Dose-Response: The vaccine is designed as a single-dose "all or nothing" trigger for the immune system. A single tablet contains sufficient viral particles (at least 32,000 tissue culture infectious doses) to ensure infection of the intestinal tract.
• Onset of Effect: Neutralizing antibodies typically begin to appear in the serum 7 to 14 days after vaccination.
• Duration of Effect: Immunity is thought to be long-lasting, providing protection throughout the high-risk period of military training (usually 6-12 months), though the exact duration of protection beyond a few years has not been definitively established.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local Intestinal Action) |

| Protein Binding | N/A |

| Peak Viral Shedding | 7–21 days post-dose |

| Duration of Shedding | Up to 28 days |

| Metabolism | Viral replication in host cells |

| Excretion | Fecal (Live Virus) |

The vaccine is a biological product. The active ingredient is the live Human Adenovirus Type 7, Strain 55142. It is grown in human diploid fibroblast cell cultures (MRC-5). The final tablet contains the virus along with excipients like microcrystalline cellulose, magnesium stearate, and the enteric coating (cellulose acetate phthalate).

This antigen belongs to the class of Live Viral Vaccines, Oral. It is unique because it uses a non-attenuated (wild-type) virus, whereas most live vaccines (like MMR or Oral Polio) use attenuated (weakened) strains. Its therapeutic area is active immunization against respiratory viral infections.